Drug Trial Radar · NCT07299747
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
255
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Dec 1, 2027
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- VelaVigo Bio IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.
Conditions
- Participants With Advanced Solid Tumor Malignancies
Interventions
VBC103Drug
VBC103
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: (DLT)From time of first dose of VBC103 to end of DLT period (approximately 21 days)
- Incidence of Serious Adverse EventsTime frame: From time of Informed Consent to 30 days post last dose of VBC103
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.